董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Victor Sandor | 男 | Director | 59 | 61.30万美元 | 3.20 | 2025-09-03 |
| Jeffrey Albers | 男 | Director | 53 | 63.80万美元 | 9.55 | 2025-09-03 |
| Pamela Esposito | 女 | Director | 51 | 63.06万美元 | 6.82 | 2025-09-03 |
| Nello Mainolfi | -- | President, Chief Executive Officer and Director | 47 | 854.56万美元 | 286.61 | 2025-09-03 |
| Gorjan Hrustanovic | 男 | Director | 36 | 61.80万美元 | 8.42 | 2025-09-03 |
| Elena Ridloff | 女 | Director | 45 | 63.30万美元 | 6.41 | 2025-09-03 |
| ジョンマラガノア | 男 | Director | 63 | 62.05万美元 | 未持股 | 2025-09-03 |
| Felix J. Baker | 男 | Lead Independent Director | 56 | 未披露 | 未持股 | 2025-09-03 |
| Victor Sandor | 男 | Director | 58 | 未披露 | 未持股 | 2025-09-03 |
| Elena Ridloff | 女 | Director | 45 | 未披露 | 未持股 | 2025-09-03 |
| Felix J. Baker | 男 | Lead Independent Director | 55 | 63.69万美元 | 600.84 | 2025-09-03 |
| Bruce Booth | 男 | Chairman | 50 | 64.30万美元 | 8.42 | 2025-09-03 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Brian R. Adams | 男 | Chief Legal Officer | 52 | 607.10万美元 | 未持股 | 2025-09-03 |
| Nello Mainolfi | -- | President, Chief Executive Officer and Director | 47 | 854.56万美元 | 286.61 | 2025-09-03 |
| Bruce Jacobs | 男 | Chief Financial Officer | 56 | 290.32万美元 | 79.36 | 2025-09-03 |
| Jared Gollob | 男 | Chief Medical Officer | 61 | 291.43万美元 | 56.98 | 2025-09-03 |
| Jeremy Chadwick | 男 | Chief Operating Officer | 62 | 346.22万美元 | 15.25 | 2025-09-03 |
| Noah Goodman | 男 | Chief Business Officer | 38 | 317.21万美元 | 未持股 | 2025-09-03 |
董事简历
中英对照 | 中文 | 英文- Victor Sandor
-
Victor Sandor，自2022年11月起担任董事会成员。他最近担任Array Biopharma， Inc.（或Array）的首席医疗官（从2014年9月到2019年7月被Pfizer Inc.收购）。他也是Prelude Therapeutics Incorporated（上市的精密肿瘤学公司）、ADCT Therapeutics SA（上市的抗体药物偶联公司）和Merus n.v。（上市的肿瘤学公司）的董事会成员。他还担任一家私人控股公司的董事会成员。在加入Array之前，他曾担任Incyte Corporation的全球临床开发高级副总裁。他也是Biogen Idec的副总裁兼肿瘤学首席医疗官，并在AstraZeneca担任肿瘤学产品开发的职位。他在McGill大学获得医学硕士学位，并在美国国立卫生研究院完成了医学肿瘤学研究。
Victor Sandor,has served as a member of Board since May 2020. From September 2014 to December 2019, Dr. Sandor served as the Chief Medical Officer at Array BioPharma Inc., a pharmaceutical company. From February 2010 to September 2014, he served as Vice President and then Senior Vice President for Global Clinical Development at Incyte Corporation, a pharmaceutical company. From November 2009 to February 2010, Dr. Sandor served as the Vice President and Chief Medical Officer for oncology at Biogen Idec and, from September 2002 to November 2009, held positions of increasing responsibility in oncology product development at AstraZeneca. Dr. Sandor has served on the board of directors of Kymera Therapeutics since November of 2022, ADC Therapeutics SA since April 2020, Istarti Oncology since July 2019, and Merus N.V. since June 2019. Dr. Sandor received a M.D.C.M. from McGill University in Montreal, Canada, and completed his Fellowship in Medical Oncology at the National Institutes of Health in Bethesda, Maryland. - Victor Sandor，自2022年11月起担任董事会成员。他最近担任Array Biopharma， Inc.（或Array）的首席医疗官（从2014年9月到2019年7月被Pfizer Inc.收购）。他也是Prelude Therapeutics Incorporated（上市的精密肿瘤学公司）、ADCT Therapeutics SA（上市的抗体药物偶联公司）和Merus n.v。（上市的肿瘤学公司）的董事会成员。他还担任一家私人控股公司的董事会成员。在加入Array之前，他曾担任Incyte Corporation的全球临床开发高级副总裁。他也是Biogen Idec的副总裁兼肿瘤学首席医疗官，并在AstraZeneca担任肿瘤学产品开发的职位。他在McGill大学获得医学硕士学位，并在美国国立卫生研究院完成了医学肿瘤学研究。
- Victor Sandor,has served as a member of Board since May 2020. From September 2014 to December 2019, Dr. Sandor served as the Chief Medical Officer at Array BioPharma Inc., a pharmaceutical company. From February 2010 to September 2014, he served as Vice President and then Senior Vice President for Global Clinical Development at Incyte Corporation, a pharmaceutical company. From November 2009 to February 2010, Dr. Sandor served as the Vice President and Chief Medical Officer for oncology at Biogen Idec and, from September 2002 to November 2009, held positions of increasing responsibility in oncology product development at AstraZeneca. Dr. Sandor has served on the board of directors of Kymera Therapeutics since November of 2022, ADC Therapeutics SA since April 2020, Istarti Oncology since July 2019, and Merus N.V. since June 2019. Dr. Sandor received a M.D.C.M. from McGill University in Montreal, Canada, and completed his Fellowship in Medical Oncology at the National Institutes of Health in Bethesda, Maryland.
- Jeffrey Albers
-
Jeffrey Albers自2020年7月以来一直是我们的董事会成员。2014年7月，他加入Blueprint Medicines Corp.，担任首席执行官和董事会成员。他领导研究阶段的公司通过首次公开募股，现在是一个完全集成的全球生物技术公司。他此前曾担任Algeta ASA公司的总裁（从2012年1月到2014年4月），在那里他曾监管公司被Bayer公司收购之前靶向癌症疗法的成功商业启动。任职Algeta公司之前，他曾担任Genzyme公司（现为Sanofi公司的一个部门）的高级商业和公司开发职务（从2005年7月到2011年11月），最近担任美国血液和肿瘤业务部门的Vice President。Albers从2000年到2005年担任Mintz Levin Cohn Ferris Glovsky&Popeo生命科学公司律师。他目前任职于MagentaTherapeutics，Inc.公司（一家公开上市的生物技术公司）和美国癌症协会新英格兰东部分会的董事会，也是生命科学关怀顾问委员会的成员。他持有Indiana University的工商管理硕士学位，以及Georgetown University的工商管理硕士学位和法学博士学位。
Jeffrey Albers,has served as a member of board of directors since July 2020. He currently serves as the Chair of the board of directors of Blueprint Medicines Corp., or Blueprint, and served as Blueprint's Executive Chair from April to December 2022 and Chief Executive Officer from July 2014 to August 2022, and as a member of the board of directors since July 2014. During that time, he led the research-stage company through an initial public offering and now to a fully integrated, global biotechnology company. Mr. Albers previously served as President of Algeta ASA from January 2012 to April 2014, where he oversaw the successful commercial launch of a targeted cancer therapy prior to its acquisition by Bayer in April 2014. Prior to Algeta ASA, he held senior commercial and corporate development positions at Genzyme Corporation (now a division of Sanofi) from July 2005 to November 2011, most recently as vice president of the U.S. hematology and oncology business unit. Earlier in his career from 2000 to 2005, Mr. Albers was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo. He currently serves as the Chair of the board of directors of Spyre Therapeutics, a publicly traded biotechnology company and serves as a member of the board of directors of several privately held companies. He currently serves as a Venture Partner at Atlas Venture and is on the Board of Advisors for Life Sciences Cares. He holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University. - Jeffrey Albers自2020年7月以来一直是我们的董事会成员。2014年7月，他加入Blueprint Medicines Corp.，担任首席执行官和董事会成员。他领导研究阶段的公司通过首次公开募股，现在是一个完全集成的全球生物技术公司。他此前曾担任Algeta ASA公司的总裁（从2012年1月到2014年4月），在那里他曾监管公司被Bayer公司收购之前靶向癌症疗法的成功商业启动。任职Algeta公司之前，他曾担任Genzyme公司（现为Sanofi公司的一个部门）的高级商业和公司开发职务（从2005年7月到2011年11月），最近担任美国血液和肿瘤业务部门的Vice President。Albers从2000年到2005年担任Mintz Levin Cohn Ferris Glovsky&Popeo生命科学公司律师。他目前任职于MagentaTherapeutics，Inc.公司（一家公开上市的生物技术公司）和美国癌症协会新英格兰东部分会的董事会，也是生命科学关怀顾问委员会的成员。他持有Indiana University的工商管理硕士学位，以及Georgetown University的工商管理硕士学位和法学博士学位。
- Jeffrey Albers,has served as a member of board of directors since July 2020. He currently serves as the Chair of the board of directors of Blueprint Medicines Corp., or Blueprint, and served as Blueprint's Executive Chair from April to December 2022 and Chief Executive Officer from July 2014 to August 2022, and as a member of the board of directors since July 2014. During that time, he led the research-stage company through an initial public offering and now to a fully integrated, global biotechnology company. Mr. Albers previously served as President of Algeta ASA from January 2012 to April 2014, where he oversaw the successful commercial launch of a targeted cancer therapy prior to its acquisition by Bayer in April 2014. Prior to Algeta ASA, he held senior commercial and corporate development positions at Genzyme Corporation (now a division of Sanofi) from July 2005 to November 2011, most recently as vice president of the U.S. hematology and oncology business unit. Earlier in his career from 2000 to 2005, Mr. Albers was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo. He currently serves as the Chair of the board of directors of Spyre Therapeutics, a publicly traded biotechnology company and serves as a member of the board of directors of several privately held companies. He currently serves as a Venture Partner at Atlas Venture and is on the Board of Advisors for Life Sciences Cares. He holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University.
- Pamela Esposito
-
Pamela Esposito博士自2015年以来一直担任我们的首席商务官。此前，她曾于2013年至2015年担任RaPharmaceuticals，Inc.首席商务官。作为RaPharmaceuticals，Inc.高级管理团队的一员，埃斯波西托博士在战略方面发挥了领导作用，帮助RaPharmaceuticals，Inc.从一个发现平台转变为一个处于临床阶段的公司。在加入RaPharmaceuticals，Inc.之前，从2010年到2011年，她是Biovex Group，Inc.业务发展的Vice President。Esposito博士于2002年在塔夫茨大学医学院获得药理学博士学位，并在达特茅斯学院（Dartmouth College）获得生物化学/分子生物学学士学位。
Pamela Esposito,has served as Replimune Group, Inc. Chief Business Officer since 2015. Previously, she was Chief Business Officer at Ra Pharmaceuticals, Inc. from 2013 to 2015. As a member of Ra Pharmaceuticals, Inc.'s senior management team, Dr. Esposito played a leadership role in strategy, helping Ra Pharmaceuticals, Inc. transform from a discovery platform to a clinical-stage company. Prior to Ra Pharmaceuticals, Inc., from 2010 to 2011, she was Vice President of Business Development at BioVex Group, Inc. Dr. Esposito currently serves on the board of directors of Accent Therapeutics, Inc., a privately held company, and Kymera Therapeutics, Inc., a Nasdaq-listed company. Dr. Esposito earned a Ph.D. in Pharmacology from Tufts University School of Medicine in 2002 and a B.A. in Biochemistry/Molecular Biology from Dartmouth College. - Pamela Esposito博士自2015年以来一直担任我们的首席商务官。此前，她曾于2013年至2015年担任RaPharmaceuticals，Inc.首席商务官。作为RaPharmaceuticals，Inc.高级管理团队的一员，埃斯波西托博士在战略方面发挥了领导作用，帮助RaPharmaceuticals，Inc.从一个发现平台转变为一个处于临床阶段的公司。在加入RaPharmaceuticals，Inc.之前，从2010年到2011年，她是Biovex Group，Inc.业务发展的Vice President。Esposito博士于2002年在塔夫茨大学医学院获得药理学博士学位，并在达特茅斯学院（Dartmouth College）获得生物化学/分子生物学学士学位。
- Pamela Esposito,has served as Replimune Group, Inc. Chief Business Officer since 2015. Previously, she was Chief Business Officer at Ra Pharmaceuticals, Inc. from 2013 to 2015. As a member of Ra Pharmaceuticals, Inc.'s senior management team, Dr. Esposito played a leadership role in strategy, helping Ra Pharmaceuticals, Inc. transform from a discovery platform to a clinical-stage company. Prior to Ra Pharmaceuticals, Inc., from 2010 to 2011, she was Vice President of Business Development at BioVex Group, Inc. Dr. Esposito currently serves on the board of directors of Accent Therapeutics, Inc., a privately held company, and Kymera Therapeutics, Inc., a Nasdaq-listed company. Dr. Esposito earned a Ph.D. in Pharmacology from Tufts University School of Medicine in 2002 and a B.A. in Biochemistry/Molecular Biology from Dartmouth College.
- Nello Mainolfi
-
Nello Mainolfi自2019年11月起担任我们的联合创始人，总裁，首席执行官和董事会成员。此前，Mainolfi博士于2019年6月至2019年11月担任总裁兼首席科学官，于2019年1月至2019年6月担任首席科学官，于2017年10月至2019年1月担任首席技术官，并于2016年5月至2017年9月担任药物发现Vice President。创立Kymera之前，Mainolfi博士于2016年1月至2018年6月担任Atlas Venture的常驻企业家，此后一直担任顾问。从2015年1月至2016年4月，Mainolfi博士还在Raze Therapeutics，Inc.担任过各种职务，包括从2016年1月至2016年4月担任高级董事，药物发现主管，从2015年1月至2016年1月担任董事，化学主管。在此之前，Mainolfi博士于2007年10月至2015年1月在诺华生物医学研究所（Novartis Institutes for Biomedical Research）工作，领导团队识别跨一系列疾病领域进入临床开发的多个潜在新药。Mainolfi博士拥有伦敦大学国王学院（King&8217；s College）的博士学位和伦敦大学玛丽皇后学院（Queen Mary，University of London）的理学学士学位。
Nello Mainolfi,has served as co-founder, President, Chief Executive Officer and a member of board of directors since November 2019. Previously, Dr. Mainolfi served as President and Chief Scientific Officer from June 2019 to November 2019, Chief Scientific Officer from January 2019 to June 2019, Chief Technology Officer from October 2017 to January 2019, and Vice President of Drug Discovery from May 2016 to September 2017. Prior to founding Kymera, Dr. Mainolfi was an entrepreneur in residence at Atlas Venture from January 2016 to June 2018 and has since transitioned to a role as an advisor. From January 2015 to April 2016, Dr. Mainolfi also held various roles at Raze Therapeutics, Inc., including as the Senior Director, Head of Drug Discovery from January 2016 to April 2016 and as Director, Head of Chemistry from January 2015 to January 2016. Prior to that, Dr. Mainolfi worked at the Novartis Institutes for Biomedical Research from October 2007 to January 2015, leading teams to identify multiple novel potential medicines that have entered clinical development across a series of disease areas. Dr. Mainolfi holds a Ph.D. from King's College, University of London and a BSc from Queen Mary, University of London. - Nello Mainolfi自2019年11月起担任我们的联合创始人，总裁，首席执行官和董事会成员。此前，Mainolfi博士于2019年6月至2019年11月担任总裁兼首席科学官，于2019年1月至2019年6月担任首席科学官，于2017年10月至2019年1月担任首席技术官，并于2016年5月至2017年9月担任药物发现Vice President。创立Kymera之前，Mainolfi博士于2016年1月至2018年6月担任Atlas Venture的常驻企业家，此后一直担任顾问。从2015年1月至2016年4月，Mainolfi博士还在Raze Therapeutics，Inc.担任过各种职务，包括从2016年1月至2016年4月担任高级董事，药物发现主管，从2015年1月至2016年1月担任董事，化学主管。在此之前，Mainolfi博士于2007年10月至2015年1月在诺华生物医学研究所（Novartis Institutes for Biomedical Research）工作，领导团队识别跨一系列疾病领域进入临床开发的多个潜在新药。Mainolfi博士拥有伦敦大学国王学院（King&8217；s College）的博士学位和伦敦大学玛丽皇后学院（Queen Mary，University of London）的理学学士学位。
- Nello Mainolfi,has served as co-founder, President, Chief Executive Officer and a member of board of directors since November 2019. Previously, Dr. Mainolfi served as President and Chief Scientific Officer from June 2019 to November 2019, Chief Scientific Officer from January 2019 to June 2019, Chief Technology Officer from October 2017 to January 2019, and Vice President of Drug Discovery from May 2016 to September 2017. Prior to founding Kymera, Dr. Mainolfi was an entrepreneur in residence at Atlas Venture from January 2016 to June 2018 and has since transitioned to a role as an advisor. From January 2015 to April 2016, Dr. Mainolfi also held various roles at Raze Therapeutics, Inc., including as the Senior Director, Head of Drug Discovery from January 2016 to April 2016 and as Director, Head of Chemistry from January 2015 to January 2016. Prior to that, Dr. Mainolfi worked at the Novartis Institutes for Biomedical Research from October 2007 to January 2015, leading teams to identify multiple novel potential medicines that have entered clinical development across a series of disease areas. Dr. Mainolfi holds a Ph.D. from King's College, University of London and a BSc from Queen Mary, University of London.
- Gorjan Hrustanovic
-
Gorjan Hrustanovic，自2020年3月起担任董事会成员。Hrustanovic博士是BVF Partners L.P.的董事总经理，他专注于生物技术和治疗投资。Hrustanovic博士是Olema Pharmaceuticals, Inc.的董事会成员，该公司是一家上市的生物制药公司，并担任多家私营公司的董事会成员。Hrustanovic博士在加州大学圣地亚哥分校获得分子生物学和经济学/管理科学学士学位，在加州大学旧金山分校获得生物医学科学、癌症生物学和细胞信号博士学位。
Gorjan Hrustanovic,has served as a member of board of directors since March 2020. Dr. Hrustanovic is a Managing Director at BVF Partners L.P. where he focuses on biotechnology and therapeutic investments. Dr. Hrustanovic is a member of the board of directors of Olema Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, and serves as a member of the board of directors of several privately held companies. Dr. Hrustanovic received his B.S. in molecular biology and economics/management science from the University of California, San Diego and a Ph.D. in Biomedical Sciences, Cancer Biology and Cell Signaling from the University of California, San Francisco. - Gorjan Hrustanovic，自2020年3月起担任董事会成员。Hrustanovic博士是BVF Partners L.P.的董事总经理，他专注于生物技术和治疗投资。Hrustanovic博士是Olema Pharmaceuticals, Inc.的董事会成员，该公司是一家上市的生物制药公司，并担任多家私营公司的董事会成员。Hrustanovic博士在加州大学圣地亚哥分校获得分子生物学和经济学/管理科学学士学位，在加州大学旧金山分校获得生物医学科学、癌症生物学和细胞信号博士学位。
- Gorjan Hrustanovic,has served as a member of board of directors since March 2020. Dr. Hrustanovic is a Managing Director at BVF Partners L.P. where he focuses on biotechnology and therapeutic investments. Dr. Hrustanovic is a member of the board of directors of Olema Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, and serves as a member of the board of directors of several privately held companies. Dr. Hrustanovic received his B.S. in molecular biology and economics/management science from the University of California, San Diego and a Ph.D. in Biomedical Sciences, Cancer Biology and Cell Signaling from the University of California, San Francisco.
- Elena Ridloff
-
Elena Ridloff，自2021年9月起担任Sionna Therapeutics，Inc. 首席财务官兼企业发展主管。此前，Ridloff女士曾于2018年至2021年在Acadia Pharmaceuticals Inc.（纳斯达克股票代码：ACAD）担任多个职务，最近一次是在2018年10月至2021年9月担任首席财务官。Ridloff女士还自2021年3月起担任Kymera Therapeutics, Inc.（纳斯达克股票代码：KYMR）（“Kymera”）的董事会成员，自2020年9月起担任Kronos Bio, Inc.（纳斯达克股票代码：KRON）的董事会成员。里德洛夫女士获得了宾夕法尼亚大学科学史和社会学学士学位，是一名特许金融分析师。
Elena Ridloff,has served as Sionna Therapeutics, Inc. Chief Financial Officer and Head of Corporate Development since September 2021. Previously, Ms. Ridloff served in multiple roles at Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) from 2018 to 2021, including most recently as chief financial officer from October 2018 to September 2021. Ms. Ridloff has also served on the board of directors of Kymera Therapeutics, Inc. (NASDAQ: KYMR) ("Kymera"), since March 2021 and Kronos Bio, Inc. (NASDAQ: KRON) since September 2020. Ms. Ridloff earned a B.A. in history and sociology of science from the University of Pennsylvania and is a Chartered Financial Analyst. - Elena Ridloff，自2021年9月起担任Sionna Therapeutics，Inc. 首席财务官兼企业发展主管。此前，Ridloff女士曾于2018年至2021年在Acadia Pharmaceuticals Inc.（纳斯达克股票代码：ACAD）担任多个职务，最近一次是在2018年10月至2021年9月担任首席财务官。Ridloff女士还自2021年3月起担任Kymera Therapeutics, Inc.（纳斯达克股票代码：KYMR）（“Kymera”）的董事会成员，自2020年9月起担任Kronos Bio, Inc.（纳斯达克股票代码：KRON）的董事会成员。里德洛夫女士获得了宾夕法尼亚大学科学史和社会学学士学位，是一名特许金融分析师。
- Elena Ridloff,has served as Sionna Therapeutics, Inc. Chief Financial Officer and Head of Corporate Development since September 2021. Previously, Ms. Ridloff served in multiple roles at Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) from 2018 to 2021, including most recently as chief financial officer from October 2018 to September 2021. Ms. Ridloff has also served on the board of directors of Kymera Therapeutics, Inc. (NASDAQ: KYMR) ("Kymera"), since March 2021 and Kronos Bio, Inc. (NASDAQ: KRON) since September 2020. Ms. Ridloff earned a B.A. in history and sociology of science from the University of Pennsylvania and is a Chartered Financial Analyst.
- ジョンマラガノア
-
John Maraganore自2023年9月起担任City Therapeutics，Inc.的执行主席和City Therapeutics，Inc.的董事会成员。Maraganore博士自2022年1月起担任战略咨询公司JMM Innovations，LLC的负责人，并自2024年9月起担任私营生物技术公司Corsera Health，Inc.的联合首席执行官。他目前还担任ARCH Venture Partners的风险合伙人、Atlas Venture的风险顾问、Blackstone Life Sciences的高级顾问、杰富瑞金融服务的高级顾问，以及RTW Investments，LP的执行合伙人，RTW Investments，LP均为一家投资和风险投资公司。此前，Maraganore博士曾于2002年12月至2021年12月担任Alnylam的创始首席执行官和董事会成员，并于2002年12月至2007年12月担任Alnylam的总裁。Maraganore博士目前在Kymera Therapeutics, Inc.（纳斯达克：KYMR）、Beam Therapeutics Inc.（纳斯达克：BEAM）（“Beam Therapeutics”）、Rapport Therapeutics，Inc.（纳斯达克：RAPP）、Hemab Therapeutics Holdings，Inc.（丨纳斯达克纳斯达克：COAG）和Takeda Pharmaceutical Company Limited（纽约证券交易所代码：TAK）的董事会任职。他此前曾于2010年6月至2023年5月在Agios制药公司（纳斯达克：纳斯达克：AGIO）董事会任职，于2022年8月至2024年5月在ProKidney Corp.（TERM3：PROK）董事会任职。Maraganore博士分别在芝加哥大学获得生物科学学士学位和生物化学和分子生物学硕士学位和博士学位。
John Maraganore has served as City Therapeutics, Inc.'s Executive Chair and a member of City Therapeutics, Inc.'s board of directors since September 2023. Dr. Maraganore has served as Principal of JMM Innovations, LLC, a strategic consulting firm, since January 2022, and as Co Chief Executive Officer of Corsera Health, Inc., a privately held biotechnology company, since September 2024. He also currently serves as a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Venture, a Senior Advisor at Blackstone Life Sciences, a Senior Advisor at Jefferies Financial Services, and an Executive Partner at RTW Investments, LP, each an investment and venture capital firm. Previously, Dr. Maraganore served as founding Chief Executive Officer and as a member of the board of directors of Alnylam from December 2002 to December 2021, and as President of Alnylam from December 2002 to December 2007. Dr. Maraganore currently serves on the boards of directors of Kymera Therapeutics, Inc. (Nasdaq: KYMR), Beam Therapeutics Inc. (Nasdaq: BEAM) ("Beam Therapeutics"), Rapport Therapeutics, Inc. (Nasdaq: RAPP), Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) and Takeda Pharmaceutical Company Limited (NYSE: TAK). He previously served on the boards of directors of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) from June 2010 to May 2023 and ProKidney Corp. (Nasdaq: PROK) from August 2022 to May 2024. Dr. Maraganore received a B.A. in Biological Sciences and M.S. and Ph.D. degrees in Biochemistry and Molecular Biology, each from the University of Chicago. - John Maraganore自2023年9月起担任City Therapeutics，Inc.的执行主席和City Therapeutics，Inc.的董事会成员。Maraganore博士自2022年1月起担任战略咨询公司JMM Innovations，LLC的负责人，并自2024年9月起担任私营生物技术公司Corsera Health，Inc.的联合首席执行官。他目前还担任ARCH Venture Partners的风险合伙人、Atlas Venture的风险顾问、Blackstone Life Sciences的高级顾问、杰富瑞金融服务的高级顾问，以及RTW Investments，LP的执行合伙人，RTW Investments，LP均为一家投资和风险投资公司。此前，Maraganore博士曾于2002年12月至2021年12月担任Alnylam的创始首席执行官和董事会成员，并于2002年12月至2007年12月担任Alnylam的总裁。Maraganore博士目前在Kymera Therapeutics, Inc.（纳斯达克：KYMR）、Beam Therapeutics Inc.（纳斯达克：BEAM）（“Beam Therapeutics”）、Rapport Therapeutics，Inc.（纳斯达克：RAPP）、Hemab Therapeutics Holdings，Inc.（丨纳斯达克纳斯达克：COAG）和Takeda Pharmaceutical Company Limited（纽约证券交易所代码：TAK）的董事会任职。他此前曾于2010年6月至2023年5月在Agios制药公司（纳斯达克：纳斯达克：AGIO）董事会任职，于2022年8月至2024年5月在ProKidney Corp.（TERM3：PROK）董事会任职。Maraganore博士分别在芝加哥大学获得生物科学学士学位和生物化学和分子生物学硕士学位和博士学位。
- John Maraganore has served as City Therapeutics, Inc.'s Executive Chair and a member of City Therapeutics, Inc.'s board of directors since September 2023. Dr. Maraganore has served as Principal of JMM Innovations, LLC, a strategic consulting firm, since January 2022, and as Co Chief Executive Officer of Corsera Health, Inc., a privately held biotechnology company, since September 2024. He also currently serves as a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Venture, a Senior Advisor at Blackstone Life Sciences, a Senior Advisor at Jefferies Financial Services, and an Executive Partner at RTW Investments, LP, each an investment and venture capital firm. Previously, Dr. Maraganore served as founding Chief Executive Officer and as a member of the board of directors of Alnylam from December 2002 to December 2021, and as President of Alnylam from December 2002 to December 2007. Dr. Maraganore currently serves on the boards of directors of Kymera Therapeutics, Inc. (Nasdaq: KYMR), Beam Therapeutics Inc. (Nasdaq: BEAM) ("Beam Therapeutics"), Rapport Therapeutics, Inc. (Nasdaq: RAPP), Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) and Takeda Pharmaceutical Company Limited (NYSE: TAK). He previously served on the boards of directors of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) from June 2010 to May 2023 and ProKidney Corp. (Nasdaq: PROK) from August 2022 to May 2024. Dr. Maraganore received a B.A. in Biological Sciences and M.S. and Ph.D. degrees in Biochemistry and Molecular Biology, each from the University of Chicago.
- Felix J. Baker
-
Felix J. Baker，自2024年3月起担任首席独立董事，并担任Kymera Therapeutics董事会董事。贝克博士是贝克兄弟投资公司的管理成员，该公司是贝克博士与他的兄弟Julian Baker于2000年创立的。贝克博士拥有斯坦福大学免疫学学士和博士学位，他还在那里完成了两年的医学院学习。他在Bicycle治疗 PLC、Kodiak Sciences，Inc.、Kiniksa Pharmaceuticals, Ltd.、IGM Biosciences，Inc.的董事会任职。
Felix J. Baker,has served as Lead Independent Director and on Kymera Therapeutics, Inc. board of directors since March 2024. Dr. Baker is a Managing Member of Baker Brothers Investments which Dr. Baker founded, together with his brother Julian Baker, in 2000. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. He serves on the boards of Bicycle Therapeutics PLC, Kodiak Sciences, Inc., Kiniksa Pharmaceuticals, Ltd., and IGM Biosciences, Inc. - Felix J. Baker，自2024年3月起担任首席独立董事，并担任Kymera Therapeutics董事会董事。贝克博士是贝克兄弟投资公司的管理成员，该公司是贝克博士与他的兄弟Julian Baker于2000年创立的。贝克博士拥有斯坦福大学免疫学学士和博士学位，他还在那里完成了两年的医学院学习。他在Bicycle治疗 PLC、Kodiak Sciences，Inc.、Kiniksa Pharmaceuticals, Ltd.、IGM Biosciences，Inc.的董事会任职。
- Felix J. Baker,has served as Lead Independent Director and on Kymera Therapeutics, Inc. board of directors since March 2024. Dr. Baker is a Managing Member of Baker Brothers Investments which Dr. Baker founded, together with his brother Julian Baker, in 2000. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. He serves on the boards of Bicycle Therapeutics PLC, Kodiak Sciences, Inc., Kiniksa Pharmaceuticals, Ltd., and IGM Biosciences, Inc.
- Victor Sandor
-
Victor Sandor，自2022年11月起担任董事会成员。他最近的一次任职是Array生物制药，Inc.（Array）的首席医疗官，该公司于2014年9月至2019年7月被辉瑞公司收购。Sandor博士还是上市精准肿瘤学公司Prelude Therapeutics Incorporated的董事会成员、上市抗体药物偶联公司ADCT Therapeutics SA和上市肿瘤学公司Merus N.V.的董事会成员。他还担任一家私人控股公司的董事会成员。在加入Array之前，Sandor博士是因塞特医疗公司全球临床开发高级副总裁。Sandor博士还是渤健 Idec的副总裁兼肿瘤学首席医疗官，并在阿斯利康的肿瘤产品开发方面担任越来越重要的职务。Sandor博士获得了麦吉尔大学的医学博士学位，并在美国国立卫生研究院完成了他的医学肿瘤学研究金。
Victor Sandor,has served as a member of board of directors since November 2022. He was most recently Chief Medical Officer at Array Biopharma, Inc., or Array, from September 2014 until its acquisition in July 2019 by Pfizer Inc. Dr. Sandor is also a member of the board of directors of Prelude Therapeutics Incorporated, a publicly traded precision oncology company, ADCT Therapeutics SA, a publicly traded antibody drug conjugate company, and Merus N.V., a publicly traded oncology company. He also serves as a member on the board of directors of a privately held company. Prior to joining Array, Dr. Sandor was Senior Vice President for Global Clinical Development at Incyte Corporation. Dr. Sandor was also Vice President and Chief Medical Officer for Oncology at Biogen Idec and held positions of increasing responsibility in oncology product development at AstraZeneca. Dr. Sandor received his M.D.C.M. from McGill University and completed his fellowship in Medical Oncology at the National Institutes of Health. - Victor Sandor，自2022年11月起担任董事会成员。他最近的一次任职是Array生物制药，Inc.（Array）的首席医疗官，该公司于2014年9月至2019年7月被辉瑞公司收购。Sandor博士还是上市精准肿瘤学公司Prelude Therapeutics Incorporated的董事会成员、上市抗体药物偶联公司ADCT Therapeutics SA和上市肿瘤学公司Merus N.V.的董事会成员。他还担任一家私人控股公司的董事会成员。在加入Array之前，Sandor博士是因塞特医疗公司全球临床开发高级副总裁。Sandor博士还是渤健 Idec的副总裁兼肿瘤学首席医疗官，并在阿斯利康的肿瘤产品开发方面担任越来越重要的职务。Sandor博士获得了麦吉尔大学的医学博士学位，并在美国国立卫生研究院完成了他的医学肿瘤学研究金。
- Victor Sandor,has served as a member of board of directors since November 2022. He was most recently Chief Medical Officer at Array Biopharma, Inc., or Array, from September 2014 until its acquisition in July 2019 by Pfizer Inc. Dr. Sandor is also a member of the board of directors of Prelude Therapeutics Incorporated, a publicly traded precision oncology company, ADCT Therapeutics SA, a publicly traded antibody drug conjugate company, and Merus N.V., a publicly traded oncology company. He also serves as a member on the board of directors of a privately held company. Prior to joining Array, Dr. Sandor was Senior Vice President for Global Clinical Development at Incyte Corporation. Dr. Sandor was also Vice President and Chief Medical Officer for Oncology at Biogen Idec and held positions of increasing responsibility in oncology product development at AstraZeneca. Dr. Sandor received his M.D.C.M. from McGill University and completed his fellowship in Medical Oncology at the National Institutes of Health.
- Elena Ridloff
-
Elena Ridloff，自2021年3月起担任董事会成员。Ridloff女士自2021年9月起担任生命科学上市公司Sionna Therapeutics，Inc.的首席财务官兼企业发展主管。Ridloff女士此前曾担任ACADIA Pharmaceuticals Inc.（一家上市制药公司，简称ACADIA）的执行副总裁兼首席财务官。Ridloff女士于2018年4月加入ACADIA，担任投资者关系高级副总裁，领导投资者和财务沟通活动，并于2018年10月至2021年9月担任ACADIA的首席财务官。在加入ACADIA之前，Ridloff女士曾在亚力兄制药公司或Alexion担任多个职务，包括2014年4月至2016年1月投资者关系执行董事，以及2016年1月至2018年3月投资者关系副总裁。在加入Alexion之前，Ridloff女士曾于2012年1月至2014年4月担任BIOVISIO的首席执行官和管理成员，BIOVISIO是一家为生命科学行业提供战略、财务和投资者关系咨询的独立咨询公司。Ridloff女士还担任了十多年的机构投资者，2005年7月至2012年1月担任对冲基金Maverick Capital的董事总经理，负责生物技术、制药、医疗设备和生命科学领域的投资。里德洛夫女士在宾夕法尼亚大学获得了科学史和社会学学士学位，是一名特许金融分析师。Ridloff女士还担任Kronos Bio, Inc.的董事会成员，该公司是一家上市的生物技术公司。
Elena Ridloff,has served as a member of board of directors since March 2021. Ms. Ridloff has served as the Chief Financial Officer & Head of Corporate Development of Sionna Therapeutics, Inc., a publicly traded life sciences company, since September 2021. Ms. Ridloff previously served as the Executive Vice President and Chief Financial Officer of ACADIA Pharmaceuticals Inc., or ACADIA, a publicly traded pharmaceutical company. Ms. Ridloff joined ACADIA in April 2018 as Senior Vice President, Investor Relations, where she led investor and financial communications activities, and served as ACADIA's Chief Financial Officer from October 2018 to September 2021. Before ACADIA, Ms. Ridloff held various roles at Alexion Pharmaceuticals, Inc., or Alexion, including Executive Director, Investor Relations from April 2014 to January 2016, and Vice President, Investor Relations from January 2016 to March 2018. Prior to joining Alexion, Ms. Ridloff served as the Chief Executive Officer and Managing Member of BIOVISIO, an independent consulting firm providing strategic, financial and investor relations counsel to the life sciences industry, from January 2012 to April 2014. Ms. Ridloff also spent over a decade as an institutional investor and from July 2005 to January 2012 served as Managing Director at Maverick Capital, a hedge fund, where she was responsible for investments in the biotechnology, pharmaceutical, medical device and life science sectors. Ms. Ridloff earned her B.A. in history and sociology of science from the University of Pennsylvania and is a Chartered Financial Analyst. Ms. Ridloff also serves as a member on the board of directors of Kronos Bio, Inc., a publicly traded biotechnology company. - Elena Ridloff，自2021年3月起担任董事会成员。Ridloff女士自2021年9月起担任生命科学上市公司Sionna Therapeutics，Inc.的首席财务官兼企业发展主管。Ridloff女士此前曾担任ACADIA Pharmaceuticals Inc.（一家上市制药公司，简称ACADIA）的执行副总裁兼首席财务官。Ridloff女士于2018年4月加入ACADIA，担任投资者关系高级副总裁，领导投资者和财务沟通活动，并于2018年10月至2021年9月担任ACADIA的首席财务官。在加入ACADIA之前，Ridloff女士曾在亚力兄制药公司或Alexion担任多个职务，包括2014年4月至2016年1月投资者关系执行董事，以及2016年1月至2018年3月投资者关系副总裁。在加入Alexion之前，Ridloff女士曾于2012年1月至2014年4月担任BIOVISIO的首席执行官和管理成员，BIOVISIO是一家为生命科学行业提供战略、财务和投资者关系咨询的独立咨询公司。Ridloff女士还担任了十多年的机构投资者，2005年7月至2012年1月担任对冲基金Maverick Capital的董事总经理，负责生物技术、制药、医疗设备和生命科学领域的投资。里德洛夫女士在宾夕法尼亚大学获得了科学史和社会学学士学位，是一名特许金融分析师。Ridloff女士还担任Kronos Bio, Inc.的董事会成员，该公司是一家上市的生物技术公司。
- Elena Ridloff,has served as a member of board of directors since March 2021. Ms. Ridloff has served as the Chief Financial Officer & Head of Corporate Development of Sionna Therapeutics, Inc., a publicly traded life sciences company, since September 2021. Ms. Ridloff previously served as the Executive Vice President and Chief Financial Officer of ACADIA Pharmaceuticals Inc., or ACADIA, a publicly traded pharmaceutical company. Ms. Ridloff joined ACADIA in April 2018 as Senior Vice President, Investor Relations, where she led investor and financial communications activities, and served as ACADIA's Chief Financial Officer from October 2018 to September 2021. Before ACADIA, Ms. Ridloff held various roles at Alexion Pharmaceuticals, Inc., or Alexion, including Executive Director, Investor Relations from April 2014 to January 2016, and Vice President, Investor Relations from January 2016 to March 2018. Prior to joining Alexion, Ms. Ridloff served as the Chief Executive Officer and Managing Member of BIOVISIO, an independent consulting firm providing strategic, financial and investor relations counsel to the life sciences industry, from January 2012 to April 2014. Ms. Ridloff also spent over a decade as an institutional investor and from July 2005 to January 2012 served as Managing Director at Maverick Capital, a hedge fund, where she was responsible for investments in the biotechnology, pharmaceutical, medical device and life science sectors. Ms. Ridloff earned her B.A. in history and sociology of science from the University of Pennsylvania and is a Chartered Financial Analyst. Ms. Ridloff also serves as a member on the board of directors of Kronos Bio, Inc., a publicly traded biotechnology company.
- Felix J. Baker
-
Felix J. Baker，2004年4月以来担任公司的董事，目前担任董事会主席。之前，Baker博士2000年10月起，也是Private Synageva的董事，一直到合并为止，也从2003年起，担任Private Synageva的董事会主席，一直到合并为止。Baker博士和他的兄弟Julian Baker是Baker Bros. Advisors, LP. Dr. Baker的联合管理成员，1994年开始了他们基金管理职业生涯，那时他们和Tisch家族联合建立了一家生物技术投资公司。2000年，他们建立了Baker Bros。 咨询公司。Baker博士拥有斯坦福大学免疫学学士学位和博士学位，在那里，他也完成了2年的医学院课程。除了公司职位之外，Baker博士是Genomic Health和Seattle Genetics的董事，两家都是生物技术公司。Baker博士之前是AnorMED ， Ardea Bioscience， Conjuchem和Neurogen 的董事，在他的任期里，这些公司都是上市公司。
Felix J. Baker,has served as Lead Independent Director (as defined below) and on Board of Directors since October 2015. Dr. Baker is a Managing Member of Baker Bros. Advisors, a biotechnology-focused investment adviser to fund partnerships whose investors are primarily endowments and foundations, which Dr. Baker founded, together with his brother Julian Baker, in 2000. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. He serves on the boards of Kodiak Sciences, Inc., IGM Biosciences, Inc. Kymera Therapeutics, Inc., and Bicycle Therapeutics plc. - Felix J. Baker，2004年4月以来担任公司的董事，目前担任董事会主席。之前，Baker博士2000年10月起，也是Private Synageva的董事，一直到合并为止，也从2003年起，担任Private Synageva的董事会主席，一直到合并为止。Baker博士和他的兄弟Julian Baker是Baker Bros. Advisors, LP. Dr. Baker的联合管理成员，1994年开始了他们基金管理职业生涯，那时他们和Tisch家族联合建立了一家生物技术投资公司。2000年，他们建立了Baker Bros。 咨询公司。Baker博士拥有斯坦福大学免疫学学士学位和博士学位，在那里，他也完成了2年的医学院课程。除了公司职位之外，Baker博士是Genomic Health和Seattle Genetics的董事，两家都是生物技术公司。Baker博士之前是AnorMED ， Ardea Bioscience， Conjuchem和Neurogen 的董事，在他的任期里，这些公司都是上市公司。
- Felix J. Baker,has served as Lead Independent Director (as defined below) and on Board of Directors since October 2015. Dr. Baker is a Managing Member of Baker Bros. Advisors, a biotechnology-focused investment adviser to fund partnerships whose investors are primarily endowments and foundations, which Dr. Baker founded, together with his brother Julian Baker, in 2000. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. He serves on the boards of Kodiak Sciences, Inc., IGM Biosciences, Inc. Kymera Therapeutics, Inc., and Bicycle Therapeutics plc.
- Bruce Booth
-
Bruce Booth，自2020年6月起担任Sionna Therapeutics， Inc.董事会成员。Booth博士于2005年加入Atlas Venture，目前担任普通合伙人。他还曾担任武田制药有限公司（纽约证券交易所代码：TAK）、UCB生物制药公司和比尔和梅林达盖茨基金会的各种顾问。Booth博士是Kymera的联合创始人，并自2016年4月起担任其董事会主席。他还担任Vigil Neuroscience， Inc.（纳斯达克股票代码：Vigil）的董事长（2020年6月以来）。他是几家私人公司的主席或董事会成员，包括Nimbus Therapeutics， LLC, HotSpot Therapeutics, Inc., Arkuda Therapeutics, Inc.和Matchpoint Therapeutics， Inc.。他曾于2016年2月至2024年6月担任AVROBIO， Inc.（现为Tectonic Therapeutic， Inc. （NASDAQ： TECX））， 2016年2月至2023年9月担任Magenta Therapeutics， Inc.（现为Dianthus Therapeutics， Inc. （NASDAQ： DNTH））， 2014年10月至2020年7月担任Unum Therapeutics， Inc.（现为Cogent Biosciences， Inc. （NASDAQ： COGT））和几家私人公司的董事会成员。Booth博士以优异成绩获得宾夕法尼亚州立大学（Pennsylvania State University）生物化学学士学位。布斯博士是英国马歇尔学者，并获得了哲学博士学位。来自牛津大学纳菲尔德医学系的分子免疫学博士。
Bruce Booth,has served as Chairman of board of directors and has been a member of board of directors since September 2015. Dr. Booth was co-founder, President and Chief Executive Officer from September 2015 to August 2017. Dr. Booth joined Atlas Venture in 2005, and currently serves as a partner of Atlas Venture. Previously, from 2004 to 2005, Dr. Booth was a principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm, where he focused on the firm's venture capital activities. He currently serves as chair of the board of directors of Vigil Neuroscience, Inc. a publicly traded biotechnology company and as a member of the board of Sionna Therapeutics, Inc. a publicly traded biotechnology company. He also serves as either Chair or member of the board of directors of multiple privately held companies. Dr. Booth holds a D.Phil. in molecular immunology from Oxford University's Nuffield Department of Medicine and a B.S. in biochemistry from Pennsylvania State University. - Bruce Booth，自2020年6月起担任Sionna Therapeutics， Inc.董事会成员。Booth博士于2005年加入Atlas Venture，目前担任普通合伙人。他还曾担任武田制药有限公司（纽约证券交易所代码：TAK）、UCB生物制药公司和比尔和梅林达盖茨基金会的各种顾问。Booth博士是Kymera的联合创始人，并自2016年4月起担任其董事会主席。他还担任Vigil Neuroscience， Inc.（纳斯达克股票代码：Vigil）的董事长（2020年6月以来）。他是几家私人公司的主席或董事会成员，包括Nimbus Therapeutics， LLC, HotSpot Therapeutics, Inc., Arkuda Therapeutics, Inc.和Matchpoint Therapeutics， Inc.。他曾于2016年2月至2024年6月担任AVROBIO， Inc.（现为Tectonic Therapeutic， Inc. （NASDAQ： TECX））， 2016年2月至2023年9月担任Magenta Therapeutics， Inc.（现为Dianthus Therapeutics， Inc. （NASDAQ： DNTH））， 2014年10月至2020年7月担任Unum Therapeutics， Inc.（现为Cogent Biosciences， Inc. （NASDAQ： COGT））和几家私人公司的董事会成员。Booth博士以优异成绩获得宾夕法尼亚州立大学（Pennsylvania State University）生物化学学士学位。布斯博士是英国马歇尔学者，并获得了哲学博士学位。来自牛津大学纳菲尔德医学系的分子免疫学博士。
- Bruce Booth,has served as Chairman of board of directors and has been a member of board of directors since September 2015. Dr. Booth was co-founder, President and Chief Executive Officer from September 2015 to August 2017. Dr. Booth joined Atlas Venture in 2005, and currently serves as a partner of Atlas Venture. Previously, from 2004 to 2005, Dr. Booth was a principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm, where he focused on the firm's venture capital activities. He currently serves as chair of the board of directors of Vigil Neuroscience, Inc. a publicly traded biotechnology company and as a member of the board of Sionna Therapeutics, Inc. a publicly traded biotechnology company. He also serves as either Chair or member of the board of directors of multiple privately held companies. Dr. Booth holds a D.Phil. in molecular immunology from Oxford University's Nuffield Department of Medicine and a B.S. in biochemistry from Pennsylvania State University.
高管简历
中英对照 | 中文 | 英文- Brian R. Adams
Brian R.Adams自2018年3月起担任我们的总法律顾问兼秘书。亚当斯先生曾于2014年3月至2018年3月担任KeryxBiopharmaceuticals，Inc.高级副总裁，总法律顾问兼秘书。加入Keryx之前，Adams从2012年3月到2014年3月担任Algeta ASA总法律顾问，该公司被Bayer AG收购。Adams先生拥有哈佛大学（Harvard University）的学士学位和美国天主教大学哥伦布法学院（Columbus School of Law）的法学博士学位。
Brian R. Adams,has served as Chief Legal Officer and Secretary since January 2022. Previously, Mr. Adams served as General Counsel and Secretary from March 2018 to January 2022. Mr. Adams previously served as the Senior Vice President, General Counsel and Secretary at Keryx Biopharmaceuticals, Inc. from March 2014 to March 2018. Before joining Keryx, Mr. Adams served as General Counsel of Algeta ASA from March 2012 to March 2014 prior to its acquisition by Bayer AG. Mr. Adams holds a B.A. from Harvard University and a J.D. from the Catholic University of America's Columbus School of Law.- Brian R.Adams自2018年3月起担任我们的总法律顾问兼秘书。亚当斯先生曾于2014年3月至2018年3月担任KeryxBiopharmaceuticals，Inc.高级副总裁，总法律顾问兼秘书。加入Keryx之前，Adams从2012年3月到2014年3月担任Algeta ASA总法律顾问，该公司被Bayer AG收购。Adams先生拥有哈佛大学（Harvard University）的学士学位和美国天主教大学哥伦布法学院（Columbus School of Law）的法学博士学位。
- Brian R. Adams,has served as Chief Legal Officer and Secretary since January 2022. Previously, Mr. Adams served as General Counsel and Secretary from March 2018 to January 2022. Mr. Adams previously served as the Senior Vice President, General Counsel and Secretary at Keryx Biopharmaceuticals, Inc. from March 2014 to March 2018. Before joining Keryx, Mr. Adams served as General Counsel of Algeta ASA from March 2012 to March 2014 prior to its acquisition by Bayer AG. Mr. Adams holds a B.A. from Harvard University and a J.D. from the Catholic University of America's Columbus School of Law.
- Nello Mainolfi
Nello Mainolfi自2019年11月起担任我们的联合创始人，总裁，首席执行官和董事会成员。此前，Mainolfi博士于2019年6月至2019年11月担任总裁兼首席科学官，于2019年1月至2019年6月担任首席科学官，于2017年10月至2019年1月担任首席技术官，并于2016年5月至2017年9月担任药物发现Vice President。创立Kymera之前，Mainolfi博士于2016年1月至2018年6月担任Atlas Venture的常驻企业家，此后一直担任顾问。从2015年1月至2016年4月，Mainolfi博士还在Raze Therapeutics，Inc.担任过各种职务，包括从2016年1月至2016年4月担任高级董事，药物发现主管，从2015年1月至2016年1月担任董事，化学主管。在此之前，Mainolfi博士于2007年10月至2015年1月在诺华生物医学研究所（Novartis Institutes for Biomedical Research）工作，领导团队识别跨一系列疾病领域进入临床开发的多个潜在新药。Mainolfi博士拥有伦敦大学国王学院（King&8217；s College）的博士学位和伦敦大学玛丽皇后学院（Queen Mary，University of London）的理学学士学位。
Nello Mainolfi,has served as co-founder, President, Chief Executive Officer and a member of board of directors since November 2019. Previously, Dr. Mainolfi served as President and Chief Scientific Officer from June 2019 to November 2019, Chief Scientific Officer from January 2019 to June 2019, Chief Technology Officer from October 2017 to January 2019, and Vice President of Drug Discovery from May 2016 to September 2017. Prior to founding Kymera, Dr. Mainolfi was an entrepreneur in residence at Atlas Venture from January 2016 to June 2018 and has since transitioned to a role as an advisor. From January 2015 to April 2016, Dr. Mainolfi also held various roles at Raze Therapeutics, Inc., including as the Senior Director, Head of Drug Discovery from January 2016 to April 2016 and as Director, Head of Chemistry from January 2015 to January 2016. Prior to that, Dr. Mainolfi worked at the Novartis Institutes for Biomedical Research from October 2007 to January 2015, leading teams to identify multiple novel potential medicines that have entered clinical development across a series of disease areas. Dr. Mainolfi holds a Ph.D. from King's College, University of London and a BSc from Queen Mary, University of London.- Nello Mainolfi自2019年11月起担任我们的联合创始人，总裁，首席执行官和董事会成员。此前，Mainolfi博士于2019年6月至2019年11月担任总裁兼首席科学官，于2019年1月至2019年6月担任首席科学官，于2017年10月至2019年1月担任首席技术官，并于2016年5月至2017年9月担任药物发现Vice President。创立Kymera之前，Mainolfi博士于2016年1月至2018年6月担任Atlas Venture的常驻企业家，此后一直担任顾问。从2015年1月至2016年4月，Mainolfi博士还在Raze Therapeutics，Inc.担任过各种职务，包括从2016年1月至2016年4月担任高级董事，药物发现主管，从2015年1月至2016年1月担任董事，化学主管。在此之前，Mainolfi博士于2007年10月至2015年1月在诺华生物医学研究所（Novartis Institutes for Biomedical Research）工作，领导团队识别跨一系列疾病领域进入临床开发的多个潜在新药。Mainolfi博士拥有伦敦大学国王学院（King&8217；s College）的博士学位和伦敦大学玛丽皇后学院（Queen Mary，University of London）的理学学士学位。
- Nello Mainolfi,has served as co-founder, President, Chief Executive Officer and a member of board of directors since November 2019. Previously, Dr. Mainolfi served as President and Chief Scientific Officer from June 2019 to November 2019, Chief Scientific Officer from January 2019 to June 2019, Chief Technology Officer from October 2017 to January 2019, and Vice President of Drug Discovery from May 2016 to September 2017. Prior to founding Kymera, Dr. Mainolfi was an entrepreneur in residence at Atlas Venture from January 2016 to June 2018 and has since transitioned to a role as an advisor. From January 2015 to April 2016, Dr. Mainolfi also held various roles at Raze Therapeutics, Inc., including as the Senior Director, Head of Drug Discovery from January 2016 to April 2016 and as Director, Head of Chemistry from January 2015 to January 2016. Prior to that, Dr. Mainolfi worked at the Novartis Institutes for Biomedical Research from October 2007 to January 2015, leading teams to identify multiple novel potential medicines that have entered clinical development across a series of disease areas. Dr. Mainolfi holds a Ph.D. from King's College, University of London and a BSc from Queen Mary, University of London.
- Bruce Jacobs
Bruce Jacobs自2019年7月起担任我们的首席财务官。他此前曾于2004年4月至2019年6月担任总部位于波士顿的股权投资公司Westfield Capital Management或Westfield的管理合伙人，也曾担任Westfield管理委员会成员和医疗保健团队负责人。Jacobs先生以优异成绩毕业于宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania），在哈佛商学院（Harvard Business School）获得工商管理硕士学位，并是一名特许金融分析师。Jacobs先生目前担任Boys&Girls Club of Boston的董事会主席。
Bruce Jacobs,has served as Chief Financial Officer since July 2019. Mr. Jacobs has more than twenty-five years of experience in health care financial services, investment banking and equity research. He was previously managing partner for Westfield Capital Management, or Westfield, a Boston-based equity investment firm from April 2004 to June 2019, also serving on Westfield's management committee and as health care team lead. Mr. Jacobs graduated magna cum laude from the Wharton School of the University of Pennsylvania, earned an MBA from the Harvard Business School and is a Chartered Financial Analyst. Mr. Jacobs currently serves on the board of directors of the Boys & Girls Clubs of Boston and on the Board of Advisors for Life Sciences Cares.- Bruce Jacobs自2019年7月起担任我们的首席财务官。他此前曾于2004年4月至2019年6月担任总部位于波士顿的股权投资公司Westfield Capital Management或Westfield的管理合伙人，也曾担任Westfield管理委员会成员和医疗保健团队负责人。Jacobs先生以优异成绩毕业于宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania），在哈佛商学院（Harvard Business School）获得工商管理硕士学位，并是一名特许金融分析师。Jacobs先生目前担任Boys&Girls Club of Boston的董事会主席。
- Bruce Jacobs,has served as Chief Financial Officer since July 2019. Mr. Jacobs has more than twenty-five years of experience in health care financial services, investment banking and equity research. He was previously managing partner for Westfield Capital Management, or Westfield, a Boston-based equity investment firm from April 2004 to June 2019, also serving on Westfield's management committee and as health care team lead. Mr. Jacobs graduated magna cum laude from the Wharton School of the University of Pennsylvania, earned an MBA from the Harvard Business School and is a Chartered Financial Analyst. Mr. Jacobs currently serves on the board of directors of the Boys & Girls Clubs of Boston and on the Board of Advisors for Life Sciences Cares.
- Jared Gollob
Jared Gollob自2018年9月起担任首席医疗官。在加入Kymera之前，Gollob博士于2012年6月至2018年8月担任淀粉样变性病临床开发和全球医疗事务Vice President Vice President，并于2007年10月至2012年5月担任AlnylamPharmaceuticals，Inc.临床研究高级总监，在那里，他领导传染病、肿瘤学和淀粉样变性病的早期和晚期临床项目，为RNA干扰疗法在人类提供了第一个概念证明。他此前曾担任Harvard Medical School、Duke University School of Medicine的学术职务，也曾任职Dana-Farber Cancer Institute、Beth Israel Deaconess Medical Center、Duke University Medical Center，在那里他曾从事肿瘤学和免疫学的临床和实验室研究。Gollob博士在哥伦比亚大学（Columbia University）获得学士学位和医学博士学位，并分别在马萨诸塞州总医院（Massachusetts General Hospital）和达纳-法伯癌症研究所（Dana-Farber Cancer Institute）完成内科和医疗肿瘤学临床培训。
Jared Gollob,has served as Chief Medical Officer since September 2018. Prior to joining Kymera, Dr. Gollob was Vice President of Clinical Development and Global Vice President of Medical Affairs for Amyloidosis from June 2012 to August 2018 and Senior Director, Clinical Research from October 2007 to May 2012 at Alnylam Pharmaceuticals, Inc., where he led early and late-stage clinical programs in infectious disease, oncology, and amyloidosis that provided that first proof of concept in humans for RNA interference therapeutics. Dr. Gollob has previously held academic positions at Harvard Medical School and Duke University School of Medicine, and was on staff at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Duke University Medical Center, where he was engaged in both clinical and laboratory research in oncology and immunology. Dr. Gollob received his B.A. and M.D. from Columbia University and completed clinical training in internal medicine and medical oncology at Massachusetts General Hospital and the Dana-Farber Cancer Institute, respectively.- Jared Gollob自2018年9月起担任首席医疗官。在加入Kymera之前，Gollob博士于2012年6月至2018年8月担任淀粉样变性病临床开发和全球医疗事务Vice President Vice President，并于2007年10月至2012年5月担任AlnylamPharmaceuticals，Inc.临床研究高级总监，在那里，他领导传染病、肿瘤学和淀粉样变性病的早期和晚期临床项目，为RNA干扰疗法在人类提供了第一个概念证明。他此前曾担任Harvard Medical School、Duke University School of Medicine的学术职务，也曾任职Dana-Farber Cancer Institute、Beth Israel Deaconess Medical Center、Duke University Medical Center，在那里他曾从事肿瘤学和免疫学的临床和实验室研究。Gollob博士在哥伦比亚大学（Columbia University）获得学士学位和医学博士学位，并分别在马萨诸塞州总医院（Massachusetts General Hospital）和达纳-法伯癌症研究所（Dana-Farber Cancer Institute）完成内科和医疗肿瘤学临床培训。
- Jared Gollob,has served as Chief Medical Officer since September 2018. Prior to joining Kymera, Dr. Gollob was Vice President of Clinical Development and Global Vice President of Medical Affairs for Amyloidosis from June 2012 to August 2018 and Senior Director, Clinical Research from October 2007 to May 2012 at Alnylam Pharmaceuticals, Inc., where he led early and late-stage clinical programs in infectious disease, oncology, and amyloidosis that provided that first proof of concept in humans for RNA interference therapeutics. Dr. Gollob has previously held academic positions at Harvard Medical School and Duke University School of Medicine, and was on staff at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Duke University Medical Center, where he was engaged in both clinical and laboratory research in oncology and immunology. Dr. Gollob received his B.A. and M.D. from Columbia University and completed clinical training in internal medicine and medical oncology at Massachusetts General Hospital and the Dana-Farber Cancer Institute, respectively.
- Jeremy Chadwick
Jeremy Chadwick，自2023年5月起担任首席运营官。Chadwick博士在生命科学和制药行业拥有超过三十年的经验。在加入Kymera Therapeutics, Inc.之前，Chadwick博士曾于2019年1月至2023年5月在武田担任高级副总裁兼全球发展办公室研发主管。在武田任职期间，Chadwick博士的职责包括2019年1月至2022年1月的全球监管事务主管，以及管理全球药物安全、全球临床供应链和支持全球开发运营的多个团队。在被武田收购之前，Chadwick博士曾于2012年12月至2019年1月在Shire Pharmaceuticals担任集团副总裁兼临床开发业务主管。在其职业生涯的早期，Chadwick博士曾在The Medicines Company、Synta Pharmaceuticals Corp.、福泰制药 Inc.和Glaxo Group Research担任多个高级开发职务，职责广泛，包括项目管理、开发运营、法规事务、生物统计和数据管理。他在伦敦大学获得统计学硕士和博士学位，在英国德蒙特福特大学获得数学学士学位。
Jeremy Chadwick,has served as Chief Operating Officer since May 2023. Dr. Chadwick has more than thirty years of experience in the life sciences and pharmaceutical industries. Prior to joining Kymera Therapeutics, Inc. , Dr. Chadwick served as Senior Vice President, Head of Global Development Office R&D at Takeda from January 2019 to May 2023. During his time at Takeda, Dr. Chadwick's responsibilities included Head of Global Regulatory Affairs from January 2019 to January 2022, as well as managing Global Drug Safety, Global Clinical Supply Chain and several groups supporting Global Development Operations. Prior to its acquisition by Takeda, Dr. Chadwick served as Group Vice President and Head of Clinical Development Operations at Shire Pharmaceuticals from December 2012 to January 2019. Earlier in his career, Dr. Chadwick held a number of senior development roles with broad responsibilities including program management, development operations, regulatory affairs, biostatistics and data management at The Medicines Company, Synta Pharmaceuticals Corp., Vertex Pharmaceuticals Inc. and Glaxo Group Research. He earned his M.S. and Ph.D. in Statistics from the University of London and a B.S. in Mathematics from De Montfort University in the United Kingdom.- Jeremy Chadwick，自2023年5月起担任首席运营官。Chadwick博士在生命科学和制药行业拥有超过三十年的经验。在加入Kymera Therapeutics, Inc.之前，Chadwick博士曾于2019年1月至2023年5月在武田担任高级副总裁兼全球发展办公室研发主管。在武田任职期间，Chadwick博士的职责包括2019年1月至2022年1月的全球监管事务主管，以及管理全球药物安全、全球临床供应链和支持全球开发运营的多个团队。在被武田收购之前，Chadwick博士曾于2012年12月至2019年1月在Shire Pharmaceuticals担任集团副总裁兼临床开发业务主管。在其职业生涯的早期，Chadwick博士曾在The Medicines Company、Synta Pharmaceuticals Corp.、福泰制药 Inc.和Glaxo Group Research担任多个高级开发职务，职责广泛，包括项目管理、开发运营、法规事务、生物统计和数据管理。他在伦敦大学获得统计学硕士和博士学位，在英国德蒙特福特大学获得数学学士学位。
- Jeremy Chadwick,has served as Chief Operating Officer since May 2023. Dr. Chadwick has more than thirty years of experience in the life sciences and pharmaceutical industries. Prior to joining Kymera Therapeutics, Inc. , Dr. Chadwick served as Senior Vice President, Head of Global Development Office R&D at Takeda from January 2019 to May 2023. During his time at Takeda, Dr. Chadwick's responsibilities included Head of Global Regulatory Affairs from January 2019 to January 2022, as well as managing Global Drug Safety, Global Clinical Supply Chain and several groups supporting Global Development Operations. Prior to its acquisition by Takeda, Dr. Chadwick served as Group Vice President and Head of Clinical Development Operations at Shire Pharmaceuticals from December 2012 to January 2019. Earlier in his career, Dr. Chadwick held a number of senior development roles with broad responsibilities including program management, development operations, regulatory affairs, biostatistics and data management at The Medicines Company, Synta Pharmaceuticals Corp., Vertex Pharmaceuticals Inc. and Glaxo Group Research. He earned his M.S. and Ph.D. in Statistics from the University of London and a B.S. in Mathematics from De Montfort University in the United Kingdom.
- Noah Goodman
诺亚·古德曼，2025年4月担任首席商务官。Goodman先生在生命科学和制药行业拥有超过十五年的经验。在加入之前，Goodman先生于2021年5月至2025年4月期间在nChroma Bio（前身为Chroma Medicine）担任越来越多的职务，包括担任总裁和首席商务官。在Goodman先生受雇于nChroma Bio之前，他曾于2019年8月至2021年3月在Cadent Therapeutics（被诺华收购）担任执行董事和业务发展主管。在其职业生涯的早期，Goodman先生曾在赛里斯治疗和星火治疗担任过各种业务发展职务。他还曾在Easton Associates担任高级顾问。他在密歇根大学获得了神经科学学士学位，并在宾夕法尼亚大学沃顿商学院获得了医疗保健管理MBA学位。
Noah Goodman,as Chief Business Officer in April 2025. Mr. Goodman has more than fifteen years of experience in the life sciences and pharmaceutical industries. Prior to joining, Mr. Goodman held roles of increasing responsibility at nChroma Bio (formerly known as Chroma Medicine) from May 2021 to April 2025, including as President and Chief Business Officer. Prior to Mr. Goodman's employment at nChroma Bio, he worked at Cadent Therapeutics (acquired by Novartis) as Executive Director and Head of Business Development from August 2019 to March 2021. Earlier in his career, Mr. Goodman worked at Seres Therapeutics and Spark Therapeutics in various business development roles. He also worked as a Senior Consultant at Easton Associates. He earned his B.S. in Neuroscience from the University of Michigan and MBA in Health Care Management from The Wharton School of the University of Pennsylvania.- 诺亚·古德曼，2025年4月担任首席商务官。Goodman先生在生命科学和制药行业拥有超过十五年的经验。在加入之前，Goodman先生于2021年5月至2025年4月期间在nChroma Bio（前身为Chroma Medicine）担任越来越多的职务，包括担任总裁和首席商务官。在Goodman先生受雇于nChroma Bio之前，他曾于2019年8月至2021年3月在Cadent Therapeutics（被诺华收购）担任执行董事和业务发展主管。在其职业生涯的早期，Goodman先生曾在赛里斯治疗和星火治疗担任过各种业务发展职务。他还曾在Easton Associates担任高级顾问。他在密歇根大学获得了神经科学学士学位，并在宾夕法尼亚大学沃顿商学院获得了医疗保健管理MBA学位。
- Noah Goodman,as Chief Business Officer in April 2025. Mr. Goodman has more than fifteen years of experience in the life sciences and pharmaceutical industries. Prior to joining, Mr. Goodman held roles of increasing responsibility at nChroma Bio (formerly known as Chroma Medicine) from May 2021 to April 2025, including as President and Chief Business Officer. Prior to Mr. Goodman's employment at nChroma Bio, he worked at Cadent Therapeutics (acquired by Novartis) as Executive Director and Head of Business Development from August 2019 to March 2021. Earlier in his career, Mr. Goodman worked at Seres Therapeutics and Spark Therapeutics in various business development roles. He also worked as a Senior Consultant at Easton Associates. He earned his B.S. in Neuroscience from the University of Michigan and MBA in Health Care Management from The Wharton School of the University of Pennsylvania.